Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15;130(20):3398.
doi: 10.1002/cncr.35554.

First person profile: Eileen M. O'Reilly, MD: Dr O'Reilly's research has resulted in the first new therapy in more than a decade for treatment-naïve metastatic pancreatic cancer

Mary Beth Nierengarten

First person profile: Eileen M. O'Reilly, MD: Dr O'Reilly's research has resulted in the first new therapy in more than a decade for treatment-naïve metastatic pancreatic cancer

Mary Beth Nierengarten. Cancer. .
No abstract available

PubMed Disclaimer

References

    1. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab‐paclitaxel and gemcitabine in treatment‐naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open‐label, phase 3 trial. Lancet. 2023;402(10409):1272‐1281. doi:10.1016/S0140-6736(23)01366-1
    1. FDA approves irinotecan liposome for first‐line treatment of metastatic pancreatic adenocarcinoma. Press release. US Food and Drug Administration. February 13, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...
    1. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020;38(13):1378‐1388. doi:10.1200/JCO.19.02931
    1. Golan T, Hammerl P, Reni M, et al. Maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317‐327. doi:10.1056/NEJMoa1903387
    1. FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma. Press release. US Food and Drug Administration. December 27, 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...

MeSH terms